Pierre Savatier, Nuria Montserrat, Laia Richart-Ginés, Camille Stephan-Otto Attolini, Raquel Bernad, Susana Prieto, Marta I. Sierra, Joaquín Pastor, Magdalena Zernicka-Goetz, Sonia Sánchez Martínez, Daniel Fisher, Javier Munoz, Sandrina Nóbrega-Pereira, Noelia Alcazar, Ana Martinez-Val, Gonzalo Gómez-López, Mario F. Fraga, Marta N. Shahbazi, Elisabeth Simboeck, Carmen Blanco-Aparicio, Elena Garreta, Osvaldo Graña-Castro, Alain Camasses, Irène Aksoy, Sagrario Ortega, Cian J. Lynch, Maribel Muñoz-Martin, Isabel A. Calvo, Agustín F. Fernández, Manuel Serrano, Carolina Tarantino, Spanish National Cancer Research Center (CNIO), Barcelona Institute of Science and Technology (BIST), University of Cambridge [UK] (CAM), Institute for Research in Biomedicine ( iBiMED), Universidade de Aveiro, Institut Curie [Paris], Institut cellule souche et cerveau (U846 Inserm - UCBL1), Institut National de la Recherche Agronomique (INRA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de Génétique Moléculaire de Montpellier (IGMM), Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Instituto Universitario de Oncología del Principado de Asturias [Oviedo, Spain] (IUOPA), Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Division of Biology and Biological Engineering [Pasadena, USA] (BBE), California Institute of Technology (CALTECH), Institució Catalana de Recerca i Estudis Avançats (ICREA), Centre National de la Recherche Scientifique (CNRS), Leverhulme Trust, Wellcome Trust, Generalitat de Catalunya, European Research Council, Fondation pour la Recherche Médicale, European Commission, Agence Nationale de la Recherche (France), Université de Lyon, Ministerio de Economía y Competitividad (España), Centro Nacional de Investigaciones Oncológicas (España), Institut National du Cancer (France), Ligue Nationale contre le Cancer (France), Asociación Española Contra el Cáncer, Ministerio de Ciencia, Innovación y Universidades (España), Instituto de Salud Carlos III, Agencia Estatal de Investigación (España), Principado de Asturias, Liberbank, Obra Social Cajastur, Banco Santander, Fundación Botín, Fundación 'la Caixa', Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), and KARLI, Mélanie
Pluripotent stem cells (PSCs) transition between cell states in vitro, reflecting developmental changes in the early embryo. PSCs can be stabilized in the naive state by blocking extracellular differentiation stimuli, particularly FGF–MEK signalling. Here, we report that multiple features of the naive state in human and mouse PSCs can be recapitulated without affecting FGF–MEK signalling or global DNA methylation. Mechanistically, chemical inhibition of CDK8 and CDK19 (hereafter CDK8/19) kinases removes their ability to repress the Mediator complex at enhancers. CDK8/19 inhibition therefore increases Mediator-driven recruitment of RNA polymerase II (RNA Pol II) to promoters and enhancers. This efficiently stabilizes the naive transcriptional program and confers resistance to enhancer perturbation by BRD4 inhibition. Moreover, naive pluripotency during embryonic development coincides with a reduction in CDK8/19. We conclude that global hyperactivation of enhancers drives naive pluripotency, and this can be achieved in vitro by inhibiting CDK8/19 kinase activity. These principles may apply to other contexts of cellular plasticity., M.N.S. was funded by a Leverhulme Trust early career fellowship. Work in the laboratory of M.Z.-G. was funded by the Wellcome Trust (098287/Z/12/Z) and the European Research Council (ERC) (669198). I.C. was funded by the Secretaria d’Universitats i Recerca de la Generalitat de Catalunya and European Social Fund. I.A. and P.S. were supported by the Fondation pour la Recherche Medicale (DEQ20170336757), Infrastructure Nationale en Biologie et Santé INGESTEM (ANR-11-INBS-0009), IHU-B CESAME (ANR-10-IBHU-003), LabEx REVIVE (ANR-10-LABX-73), LabEx DEVweCAN (ANR-10-LABX-0061) and LabEx CORTEX (ANR-11-LABX-0042) of University of Lyon within the programme ‘Investissements d’Avenir’ (ANR-11-IDEX-0007). Research by J.P., S.M. and C.B.-A. was supported in part by a grant from the Spanish Ministry of Economy and Competitiveness (SAF2013-44267-R) and by the CNIO. Work in the laboratory of D.F. was funded by the Institut National du Cancer (PLBIO10-068 and PLBIO15-005) and the Ligue National Contre le Cancer (EL2018.LNCC/DF). Work in the laboratory of N.M. was funded by the ERC, under the European Union Horizon 2020 research and innovation programme (StG-2014–640525_REGMAMKID), the Spanish Association Against Cancer (AECC/LABAE16006), Carlos III Health Institute (Red TerCel, CardioCel, RD16/0011/0027), Ministry of Economy and Competitiveness (MINECO) projects SAF2017–89782-R, SAF2015–72617-EXP and RYC-2014–16242, and the CERCA/Government of Catalonia (2017 SGR 1306). Work in the laboratory of S.O. was funded by SAF2013–44866-R from MINECO Spain. Work in the laboratory of M.F.F. was funded by Plan Nacional de I+D+I 2013–2016/FEDER (PI15/00892, to M.F.F. and A.F.F.); the ISCIII-Subdireccion General de Evaluación y Fomento de la Investigación and Plan Nacional de I+D+I 2008–2011/FEDER (CP11/00131, to A.F.F.); IUOPA (to M.I.S.); and the Asturias Regional Government (GRUPIN14–052, to M.F.F.). The IUOPA is supported by the Obra Social Liberbank-Cajastur, Spain. Work in the laboratory of M.S. was funded by the CNIO, the IRB and by grants from Spanish Ministry of Economy co-funded by the European Regional Development Fund (SAF2017-82613-R), ERC (ERC-2014-AdG/669622), Botin Foundation, Banco Santander (Santander Universities Global Division), laCaixa Foundation and Secretaria d’Universitats i Recerca del Departament d’Empresa i Coneixement of Catalonia (Grup de Recerca consolidat 2017 SGR 282).